FDG-PET/CT imaging-based target volume delineation for preoperative conformal radiotherapy of rectal carcinoma

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi

Volumn 20, Issue 2, 2010, Pages 67-68

  Yavuz, Melek N ^a   Topkan, Erkan ^a   Yavuz, A Aydin ^a   Aydin, Mehmet ^a   Onal, Cem ^a   Reyhan, Mehmet ^a   Ayse, Kotek ^a   Pehlivan, Berrin ^a   Yapar, A Fuat ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Gross target volume; Positron emission tomography; Radiation therapy; Rectal cancer; Treatment planning

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; IMAGING; INTERMETHOD COMPARISON; MALE; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; RADIATION DOSE; RECTUM CARCINOMA; TREATMENT PLANNING; TUMOR VOLUME;

EID: 77954639256     PISSN: 1306133X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Glynne-Jones R, Mathur P, Elton C, et al. The multidis-ciplinary management of gastrointestinal cancer. Multimodal treatment of rectal cancer. Best Pract Res Clin Gastroenterol 21: 1049-1070, 2007.
2. Sauer R, Becker H, Hohenberger W, et al. German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351: 1731-1740, 2004.
3. Frykholm GJ, Glimelius B, Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomised trial and evaluation of late secondary effects. Dis Colon Rectum 36: 564-572, 1993.
4. Glimelius B, Isacson U, Jung B, et al. Radiotherapy in addition to radical surgery in rectal cancer: Evidence for a dose response effect favouring preoperative treatment. Int J Radiat Oncol Biol Phys 37: 281-287, 1997.
5. Engels B, De Ridder M, Tournel K, et al. Preoperative Helical Tomotherapy and Megavoltage Computed To- mography for Rectal Cancer: Impact on the Irradiated Volume of Small Bowel. Int J Radiat Oncol Biol Phys 74: 1476-1480, 2009.
6. Ippolito E, Mertens I, Haustermans K, et al. IGRT in rectal cancer. Acta Oncol 47:1317-1324, 2008.
7. Ballonoff A, Kavanagh B, McCarter M, et al. Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: A Phase II trial. Am J Clin Oncol 31: 264-270, 2008.
8. Gunnlaugsson A, Kjellen E, Nilsson P, et al. Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer. Acta Oncol 46: 937-944, 2007.
9. van Baardwijk A, Baumert BG, Bosmans G, et al. The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev 32: 245-260, 2006.
10. Bruehlmeier M, Roelcke U, Schubiger PA, et al. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. J Nucl Med 45: 1851-1859, 2004.
11. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 32: 623-648; 649-650, 1991.
12. Janssen MH, Aerts HJ, Ollers MC, et al. Tumor delineation based on time-activity curve differences assessed with dynamic fluorodeoxyglucose positron emission tomography-computed tomography in rectal cancer patients. Int J Radiat Oncol Biol Phys 73: 456-465, 2009.
13. Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole body dual-modality fluorine-18-2-fluoro-2-deoxy-D- glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: Comparison with CT and PET. J Clin Oncol 22: 4357-4368, 2004.
14. Kantorova I, Lipska L, Belohlavek O, et al. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med 44: 1784-1788, 2003.
15. Rasanen JV, Sihvo EI, Knuuti MJ, et al. Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann Surg Oncol 10: 954-960, 2003.
16. Young CS, Young BL, Smith SM: Staging Hodgkin's disease with 18-FDG PET. Comparison with CT and surgery. Clin Positron Imag 1: 161-164, 1998.
17. Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 229: 526-533, 2003.
18. Osman MM, Cohade C, Nakamoto Y, et al. Clinically significant inaccurate localization of lesions with PET/CT: Frequency in 300 patients. J Nucl Med 44: 240-243, 2003.
19. Mah K, Caldwell CB, Ung YC, et al. The impact of (18)FDGPET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: A prospective study. Int J Radiat Oncol Biol Phys 52: 339-350, 2002.
20. Ciernik IF, Dizendorf E, Baumert BG, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): A feasibility study. Int J Radiat Oncol Biol Phys 57: 853-863, 2003.
21. Daisne JF, Sibomana M, Bol A, et al. Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: Influence of reconstruction algorithms. Radiother Oncol 69: 247-250, 2003.
22. Ciernik IF, Huser M, Burger C, et al. Automated functional image-guided radiation treatment planning for rectal cancer. Int J Radiat Oncol Biol Phys 62: 893-900, 2005.
23. Gondi V, Bradley K, Minesh M, et al. Impact of hybrid fluorodeoxyglucose positron-emission tomography/ computed tomography on radiotherapy planning in esophageal and nonsmall-cell-lung-cancer. Int J Radiat Oncol Biol Phys 67:187-195, 2007.
24. Mutic S, Malyapa RS, Grigsby PW, et al. PET guided IMRT for cervical carcinoma with positive paraaortic lymph nodes: A dose escalation treatment study. Int J Radiat Oncol Biol Phys 55: 28-35, 2003.
25. Vrieze O, Haustermans K, De Wewer W, et al. Is there a role of FDG-PET in radiotherapy planning in esopha-geal carcinoma? Radiat Oncol 73: 269-275, 2004.
26. Topkan E, Yavuz AA, Aydin M, et al. Comparison of CT and PET-CT based planning of radiation therapy in locally advanced pancreatic carcinoma. J Exp Clin Cancer Res 27: 41, 2008.
27. Moureau-Zabotto L, Touboul E, Lerouge D, et al. Im- pact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma. Int J Radiat Oncol Biol Phys 63: 340-345, 2005.
28. Munley MT, Marks LB, Scarfone C, et al. Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer. Challenges and prospects. Lung Cancer 23: 105-114, 1999.
29. Lammering G, De Haas D, De Ruysscher D, et al. First report on the use of dedicated combined PET-CT simulator in rectal cancer patients. Radiother Oncol 2004; 73(Suppl. 1): S441-S442.
30. Bassi MC, Turri L, Sacchetti G, et al. FDG-PET/CT imaging for staging and target volume delineation in preoperative conformal radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys 70:1423-1426, 2008.
31. Calvo FA, Domper M, Matute R, et al. 18FDG-positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 58: 528-535, 2004.
32. Gearhart SL, Frassica D, Rosen R, et al. Improved staging with pre-treatment positron emission tomography/computed tomography in low rectal cancer. Ann Surg Oncol 13: 397-404, 2006.
33. De Geus-Oei LF, Ruers TJ, Punt CJ, et al. FDG-PET in colorectal cancer. Cancer Imaging 2006; 316(Suppl.1): S71-S81.
34. Capirci C, Rampin L, Erba PA, et al. Sequential PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging 34: 1583-1593, 2007.
35. Patel DA, Chang ST, Goodman KA, et al. Impact of integrated PET/CT on variability of target volume delineation in rectal cancer. Technol Cancer Res Treat 6: 3136, 2007.
36. American Joint Committee on Cancer. Colon and rectum. Philadelphia, Lippincott-Raven, 2002: 113.
37. International Commission on Radiation Units and Measurements. ICRU report 62. Prescribing, recording, and reporting photon beam therapy (supplement to ICRU report 50). Bethesda, MD: ICRU; 1999.
38. Erdi YE, Mawlawi O, Larson SM, et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer 80(Suppl.12): 2505-2509, 1997.
39. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer. A systematic overview of 8,507 patients from 22 randomised trials. Lancet 358: 1291-1304, 2001.
40. Frass BA. The development of conformal radiation therapy. Med Phys 22: 1911-1921, 1995.
41. Bentzen SM. High-tech in radiation oncology: Should there be a ceiling? Int J Radiat Oncol Biol Phys 58: 320-330, 2004.
42. Buchmann I, Reinhardt M, Elsner K, et al. 2-(fluorine-18) Fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma: A Bicenter trial. Cancer 91: 889-899, 2001.
43. Huetenschmidt B, Sautter-Bihl ML, Lang O, et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 91: 302-310, 2001.
44. Jerusalem G, Beguin Y, Najjar F, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 12: 825-830, 2001.
45. Talbot JN, Haioun C, Rain JD, et al. [18F]-FDG positron imaging in clinical management of lymphoma patients. Crit Rev Oncol Hematol 38: 193-221, 2001.
46. Pakzad F, Groves A, Ell P: The Role of Positron Emission Tomography in the Management of Pancreatic Cancer. Semin Nucl Med 36: 248-256, 2006.
47. Erdi YE, Rosenzweig K, Erdi AK, et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Ra-diother Oncol 62: 51-60, 2002.
48. Grosu AL, Lachner R, Wiedenmann N, et al. Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C methionine-PET data for stereotactic radiotherapy using a LINAC: First clinical experience. Int J Radiat Oncol Biol Phys 56: 1450-1463, 2003.
49. Erdi YE, Mawlawi O, Larson SM, et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer 80: 2505-2509, 1997.
50. Giraud P, Grahek D, Montravers F, et al. CT and 18F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. Int J Radiat Oncol Biol Phys 49: 1249-1257, 2001.
51. Bradley J, Thorstad WL, Mutic S, et al. Impact of FDG- PET on radiation therapy volume delineation in non- small-cell lung cancer. Int J Radiat Oncol Biol Phys 59: 78-86, 2004.
52. Caldwell CB, Mah K, Ung YC, et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: The impact of 18FDGhybrid PET fusion. Int J Radiat Oncol Biol Phys 51: 923-931, 2001.
53. MacManus MP, Hicks RJ, Ball DL, et al. F-18 fluoro-deoxyglucose positron emission tomography staging in radical radiotherapy candidates with non-small-cell lung carcinoma. Cancer 92: 886-895, 2001.
54. Nestle U, Walter K, Schmidt S, et al. 18F-deoxygluco-se positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: High impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 44: 593-597, 1999.
55. Vanuytsel LJ, Vansteenkiste JF, Stroobant SG, et al. The impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small-cell lung cancer. Radiother Oncol 55: 317-324, 2000.
56. Narayan K, Hicks RJ, Jobling T, et al. A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer: Potential impact of treatment. Int J Gynecol Cancer 11: 263-271, 2001.
57. Reinhardt MJ, Ehritt-Braum C, Vogelgesang D, et al. Metastatic lymph nodes in patients with cervical cancer: Detection with MR imaging and FDG-PET. Radiology 218: 776-782, 2001.
58. Yen TC, Ng KK, Ma SY, et al. Value of dual-phase 2-fluro- 2-deoxy-D-glucose positron emission tomography in cervical cancer. J Clin Oncol 21: 3651-3658, 2003.
59. Kim NK, Baik SH, Seong JS, Kim H, Roh JK, Lee KY, Sohn SK, Cho CH. Oncologic outcomes after neoad-juvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival. Ann Surg 244: 1024-1030, 2006.
60. Bosset JF, Magnin V, Maingon P, et al. Preoperative radiochemotherapy in rectal cancer: Long-term results of a phase II clinical trials. Int J Radiat Oncol Biol Phys 46: 323-327, 2000.
61. Meade PG, Blatchford GJ, Thorson AG, et al. Preoperative chemoradiation downstages locally advanced ultrasound-staged rectal cancer. Am J Surg 170: 609-612, 1995.
62. Berger C, de Muret A, Garaud P, et al. Preoperative radiotherapy for rectal cancer: Predictive factors of tumor downstaging and residual tumor cell density (RTCD): prognostic implications. Int J Radiat Oncol Biol Phys 32: 1025-1029, 1997.
63. Kim JS, Kim JS, Cho MJ, et al. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 54: 403-408, 2002.